Nanoparticles that enhance radiotherapy
Bismuth sulfide nanoparticles engineered to selectively amplify radiation within tumors — increasing treatment effectiveness from ~5% to up to 40% tumor cell elimination, without new equipment.
With NanoProX
up to 40%
tumor cell elimination
Baseline
~5%
standard radiotherapy
Radiotherapy saves lives. But it has limits.
Cancer remains the second leading cause of death globally. Radiotherapy is a cornerstone of treatment — but its precision and efficacy remain constrained by fundamental biological and physical barriers.
people die from cancer globally
2nd leading cause of death
of cancer patients receive radiotherapy
Cornerstone of oncology treatment
tumor cells eliminated per standard session
Current baseline efficacy
Collateral damage to healthy tissue
Ionizing radiation cannot be perfectly confined to tumors. Surrounding healthy cells inevitably receive dose, causing toxicity and limiting how aggressively clinicians can treat.
Deep and resistant tumors
Tumors located deep within tissue or with hypoxic cores respond poorly to standard radiotherapy, leaving disease partially treated.
Repeated sessions required
Fractionated protocols — multiple treatment sessions over weeks — are necessary to balance efficacy against toxicity, placing burden on patients and healthcare systems.
Current radiosensitizers fall short
Existing radiosensitizing agents suffer from low efficiency, insufficient tumor specificity, or inability to reach all tumor sites — failing to meaningfully close the therapeutic gap.
The gap
Current radiosensitizers have low efficiency, lack of specificity, or are unable to reach all tumors
failing to close the therapeutic gap in precision oncology.
8×
improvement NanoProX delivers
A targeted amplifier for radiotherapy.
NanoProX delivers bismuth sulfide nanoparticles intravenously prior to radiotherapy. These nanoparticles circulate systemically and accumulate preferentially at tumor sites, acting as a localized radiation amplifier.
- Intravenously administered prior to radiotherapy
- Bismuth sulfide core with biocompatible polymer coating
- Selectively concentrates in tumors — 20% higher uptake vs. surrounding tissue
- Functions as a local radiation amplifier within the tumor microenvironment
- No new radiotherapy equipment required
- Compatible with existing clinical radiotherapy workflows
Efficacy Comparison
Tumor cell elimination per radiotherapy session
Standard Radiotherapy
~5%Baseline tumor cell elimination — limited by ionizing radiation physics
Radiotherapy + NanoProX
up to 40%Up to 8× improvement. Local radiation amplification via high-Z bismuth nanoparticles.
Absolute increase in tumor cell elimination — same radiotherapy equipment, greater oncological effect.
Core mechanism
High atomic number bismuth atoms absorb X-ray photons and emit secondary electrons, depositing lethal radiation dose locally within the tumor microenvironment.
Bi₂S₃ · Biocompatible polymer shell
High-Z radiosensitizationPrecision nanotechnology. Clinically relevant outcomes.
Intravenous Administration
NanoProX nanoparticles are administered intravenously before the radiotherapy session — no modification to the radiation delivery protocol.
Systemic Circulation
The bismuth sulfide nanoparticles, encapsulated in a biocompatible polymer shell, circulate through the bloodstream without triggering immune response.
Tumor Accumulation
Leveraging the enhanced permeability and retention (EPR) effect and active targeting mechanisms, NanoProX selectively concentrates within tumor tissue — achieving up to 20% greater concentration than surrounding healthy tissue.
Radiation Amplification
When radiotherapy is delivered, the high-Z bismuth atoms dramatically increase local energy deposition within the tumor, amplifying the lethal dose to cancer cells while the adjacent healthy tissue receives minimal additional radiation.
Core material
Bi₂S₃
Bismuth (III) sulfide — high atomic number radiosensitizer
Surface coating
Biocompatible polymer
Enables systemic circulation and immune evasion
Delivery route
Intravenous
Administered prior to radiotherapy — no new equipment needed
Why NanoProX.
NanoProX addresses the fundamental limits of current radiosensitization — delivering meaningful improvements across efficacy, selectivity, and clinical accessibility.
Higher efficacy
Up to 8× improvement in tumor cell elimination compared to standard radiotherapy alone.
Tumor selectivity
Targeted nanoparticles preferentially accumulate in tumor tissue, sparing healthy cells from unnecessary radiation dose.
No new infrastructure
Compatible with existing radiotherapy equipment globally — no capital investment required from hospitals.
Reduced treatment burden
Greater efficacy per session has the potential to reduce the number of required treatment fractions.
Nanotechnology platform
Bismuth sulfide nanoparticle platform opens avenues for imaging, combination therapies, and multi-modal treatment strategies.
Safety profile
Biocompatible polymer coating and bismuth's established safety profile provide a strong foundation for clinical translation.
Platform potential
The bismuth sulfide nanoparticle platform opens future pathways for imaging contrast agents, combination therapies, and multimodal precision oncology applications.
Bi₂S₃
Bismuth (III) sulfide platform
“We believe the future is not about irradiating more, it's about irradiating better.
And it starts with bismuth.”
More Effective
Precision amplification of radiotherapy within tumor tissue, dramatically increasing tumor cell elimination per session.
More Personalized
Nanoparticle-based radiosensitization opens pathways for treatment tailored to individual tumor biology and radiotherapy protocol.
Safer
Tumor-selective delivery and reduced radiation dose to healthy tissue — a meaningful reduction in treatment-related morbidity.
Our Science.
Peer-reviewed, preclinically validated nanotechnology built for clinical translation.
Bi₂S₃ Core coated with biocompatible polymer and targeting molecule
Nanoparticles only have effect under irradiation
Radiotherapy alone eliminates ~5% of tumor cells; with NanoProX, this increases up to 40%, an improvement of 8X.
The founding team.
NanoProX is built by a multidisciplinary team combining deep expertise in nanotechnology, oncology research, operations, and innovation strategy.
Federico Kramer
Chief Executive Officer
Leading NanoProX's strategic vision and business development, guiding the company from scientific inception toward clinical and commercial translation.
NanoProX is a science-first team with roots in chemistry, nanomaterials, radiation biology, and healthcare operations. The combination of rigorous scientific leadership and operational acumen positions us to move rapidly from bench to clinic.
Pipeline.
From scientific discovery to preclinical validation — a decade of rigorous research advancing toward the clinic.
Scientific project started at Udelar
Collaboration with USP (University of São Paulo)
In vitro breast cancer validation
NanoProX founded
In vitro lung cancer validation
In vivo biodistribution and pharmacokinetic studies
In ProgressIn vivo lung cancer validation
In ProgressLet's advance precision oncology together.
NanoProX is actively exploring partnerships with research institutions, clinical oncology centers, and strategic investors who share our vision for more effective, more precise cancer treatment.
Areas of interest
Research & Academic Institutions
Collaborations for preclinical studies, in-vivo validation, and mechanistic research.
Clinical Oncology Centers
Early access programs and co-development partnerships for clinical translation.
Strategic Investors
Investors aligned with biotech innovation, deep science, and long-term impact in oncology.
Pharmaceutical & MedTech Partners
Industrial partnerships for scale-up, formulation development, and combination therapies.